Drug-induced akathisia is a significant and common iatrogenic disorder. It involves both a subjective component of a disturbing sense of compulsion to move and an objective component of motor restlessness. Akathisia is being seen with increasing frequency in medical and surgical patients. This is due to the increased use of anti-emetics or novel adjuncts to pain control as well as more widespread use of the major psychoactive drugs throughout medicine. This review focuses on diagnostic features of the disorder as well as on possible treatment approaches. In addition, the disorder demonstrates the close anatomic and functional relationship between cortical and subcortical dopaminergic pathways. Akathisia is thus both an increasingly significant clinical problem and a fascinating glimpse at the relationship between brain function and behavior.
Get full access to this article
View all access options for this article.
References
1.
BarnesT. R. E. and BraudeW. M., Akathisia Variants and Tardive Dyskinesia, Archives of General Psychiatry, 42, pp. 874–878, 1985.
2.
StahlS. M., Akathisia and Tardive Dyskinesia, Archives of General Psychiatry, 42: Pp. 915–917, 1985.
3.
SacksO., Awakenings, Dutton, New York, 1983.
4.
Van PuttenT., The Many Faces of Akathisia, Comprehensive Psychiatry, 16, pp. 43–47, 1975.
5.
RateyJ. J. and SalzmanC., Recognizing and Managing Akathisia, Hospital Community Psychiatry, 35: 10, pp. 975–977, 1984.
6.
SteinbergS. K., Drug-induced Extrapyramidal Symptoms in the Elderly, Modern Medicine of Canada, 40: 5, pp. 473–482, 1985.
7.
BraudeW. M.CharlesI. P., and BarnesT. R. E., Coarse, Jerky Foot Tremor: Tremographic Investigation of an Objective Sign of Acute Akathisia, Psychopharmacology, 82, pp. 95–101, 1984.
8.
GibbW. R. G. and LeesA. J., The Clinical Phenomenon of Akathisia, Journal of Neurology and Neurosurgery Psychiatry, 49, pp. 861–866, 1986.
9.
MunetzM. R. and CornesC. L., Distinguishing Akathisia and Tardive Dyskinesia: A Review of the Literature, Journal of Clinical Psychopharmacology, 3: 6, pp. 343–349, 1983.
10.
CohenB. M., Akathisia: Treatment and Pathophysiology, APA Abstracts, Chicago, p. 96, 1987.
11.
MaltbieA. A. and CavenarJ. O.Jr., Akathisia Diagnosis: An Objective Test, Psychosomatics, 18, pp. 36–39, 1977.
12.
ChouinardG.AnnableL.Ross-ChouinardA., Ethopropazine and Benztropine in Neuroleptic-induced Parkinsonism, Journal of Clinical Psychiatry, 40, pp. 147–152, 1979.
13.
WeidenP. J.MannJ. J.HaasG.MattsonM., and FrancesA., Clinical Nonrecognition of Neuroleptic-induced Movement Disorders: A Cautionary Study, American Journal of Psychiatry, 144, pp. 1148–1153, 1987.
14.
BrownP., Identification of Akathisia in Oncology Patients, Journal of Psychosocial Oncology, paper submitted 1987.
15.
KeckichW. A., Neuroleptics: Violence as a Manifestation of Akathisia, Journal of the American Medical Association, 240, p. 2185, 1978.
16.
DrakeR. E. and EhrlichJ., Suicide Attempts Associated with Akathisia, American Journal of Psychiatry, 142: 4, pp. 499–501, 1985.
17.
ShearM. K.FrancesA., and WeidenP., Suicide Associated with Akathisia and Depot Fluphenazine Treatment, Journal of Clinical Psychopharmacology, 3, pp. 235–236, 1983.
18.
GoldbergR. J. and MorV., A Survey of Psychotropic Use in Terminal Cancer Patients, Psychosomatics, 26, pp. 745–751, 1985.
19.
GoldbergR. J. and CullenL. O., Use of Psychotropics in Cancer Patients, Psychosomatics, 27, pp. 687–700, 1986.
20.
WeidenP., Akathisia from Prochlorperazine, Journal of the American Medical Association, 253, p. 635, 1985.
21.
GrimesJ. D.HassanM. N., and PrestonD. N., Adverse Neurologic Effects of Metoclopramide, Canadian Medical Association Journal, 126, pp. 23–25, 1982.
22.
KrisI.TysonL. B., and GrallaR. F., Extrapyramidal Reactions with High-dose metoclopramide, New England Journal of Medicine, 309, p. 433, 1983.
23.
KrishnanK. R. R.FranceR. D., and EllinwoodE. H.Jr., Tricyclic-induced Akathisia in Patients Taking Conjugated Estrogens, American Journal of Psychiatry, 141: 5, pp. 696–697, 1984.
24.
ShenW. W., Akathisia: An Overlooked Distressing, but Treatable Condition, Journal of Nervous and Mental Diseases, 169, pp. 599–600, 1981.
25.
ShenW., Alcohol Amoxapine and Akathisia, Biologic Psychiatry, 9: 6, pp. 929–930, 1984.
26.
FuxeK. and AgnatiL. F., Receptor-receptor Interactions in the Central Nervous System. A New Integrative Mechanism in Synapses, Medicinal Research Reviews, 5: 4, pp. 441–482, 1985.
27.
SeemanM. V. and SeemanP., Molecular Psychiatry, Receptor Density and Receptor Sensitivity States, Integrated Psychiatry, 4, pp. 41–43, 1986.
28.
BrownK. W.GlenS. E., and WhiteT., Low Serum Iron Status and Akathisia, Lancer, 2, pp. 1234–1236, 1987.
29.
DonlonP. T., The Therapeutic Use of Diazepam for Akathisia, Psychosomatics, 14, pp. 222–225, 1973.
30.
GagratD.HamiltonJ., and BelmakerR. H., Intravenous Diazepam in the Treatment of Neuroleptic-induced Acute Dystonia and Akathisia, American Journal of Psychiatry, 135, pp. 1232–1233, 1978.
31.
ZubenkoG. S.CohenB. M.LipinskiJ. F., and JonasJ. M., Use of Clonidine in the Treatment of Akathisia, Psychiatry Research, 13, pp. 253–259, 1984.
32.
LipinskiJ. F.ZubenkoG. S.CohenB. M., and BarreiraP. J., Propranolol in the Treatment of Neuroleptic-induced Akathisia, American Journal of Psychiatry, 141: 3, pp. 412–315, 1984.
33.
DupuisB.CatteauJ.DumonJ-P.LibertC., and PetitH., Comparison of Propranolol, Sotalol, and Betaxolol in the Treatment of Neuroleptic-induced Akathisia, American Journal of Psychiatry, 144, pp. 803–805, 1987.
34.
RateyJ. J.SorgiP., and PolakoffS., Nadolol as a Treatment for Akathisia, American Journal of Psychiatry, 142, pp. 640–642, 1985.
35.
AdlerL.AnglistB.PeselowE.CorwinJ.MaslanskyR., and RotrosenJ., A Controlled Assessment of Propranolol in the Treatment of Neuroleptic-induced Akathesia, British Journal of Psychiatry, 149, pp. 42–45, 1986.
36.
AdlerL. A.AngristB.PeselowE.ReitanoJ., and RotrosenJ., Clonidine induced Akathisia, American Journal of Psychiatry, 144: 2, pp. 235–236, 1987.
37.
AgidY.RubergM.DuboisB., and Javoy-AgidF., Biochemical Substrates of Mental Disturbances in Parkinson's Disease, in Advances in Neurology, Volume 40, HasslerR. G. and ChristJ. F. (eds.), Raven Press, New York, pp. 211–218, 1984.
38.
MayeuxR.StermY.WilliamsJ. B. W.CafeL.FrantzA., and DyrenfurthI., Clinical and Biochemical Features of Depression in Parkinson's Disease, American Journal of Psychiatry, 143, pp. 756–759, 1986.
39.
CoteL., Basal Ganglia, in Principles of Neural Science, KandelE. and SchwartzJ. (eds.), Elsevier, New York, pp. 347–359, 1982.
40.
DelongM., Motor Functions of the Basal Ganglia, in The Neurosciences, SchmittF. and WordunF. (eds.), MIT Press, Boston, pp. 319–325, 1974.
41.
LuriaA. R., The Working Brain, HaighB. (trans.), Penguin Books, 1984.
42.
AntelmanS., Stress and Its Timing: Critical Factors in Determining the Consequences of Dopaminergic Agents, Pharmacology, Biochemistry and Behavior, 17(suppl 1), pp. 21–23, 1982.
43.
Van PraagH. M.KorfJ.LakkeJ. P. W. F., and SchutT., Dopamine Metabolism in Depressions, Psychoses, and Parkinson's Disease: The Problem of the Specificity of Biological Variables in Behaviour Disorders, Psychological Medicine, 5, pp. 138–147, 1975.
44.
GoodwinF. K.BrodieH. K.MurphyD. L., and BunneyW. E., Administration of a Peripheral Decarboxylase Inhibitor with L-dopa to Depressed Patients, Lancet, i, pp. 908–911, 1970.
45.
KanzlerM. and MalitzS., L-dopa for the Treatment of Depression, in L-Dopa and Behaviour, MalitzS. (ed.), Raven Press, New York, pp. 103–119, 1972.
46.
JouventR.AbensourP.BonnetA. M.WidlocherD.AgidY., and LhermitteF., Antiparkinsonian and Antidepressant Effects of High Doses of Bromocryptine, Journal of Affective Diseases, 5, pp. 141–145, 1982.
47.
BrownP. and BrawleyP., Dexamethasone Suppression Test and Mood Response to Methylphenidate in Primary Depression, American Journal of Psychiatry, 140, pp. 990–993, 1983.
48.
SigwalsJ., Therapeutique des syndromes extrapyramidaux par les traitements classiques, in Monoamines, noyaux gris centraux et syndrome de parkinson, de AjuriaguerraJ. and GauthierG. (eds.), Georg, Geneva, pp. 369–383, 1971.
49.
StrangR. R., Imipramine in Treatment of Parkinsonism: A Double-blind Placebo Study, British Medical Journal, ii, pp. 33–34, 1965.
50.
AsnisC., Parkinson's Disease, Depression and ECT: A Review and Case Study, American Journal of Psychiatry, 134, pp. 191–195, 1977.
51.
LebenshonZ. M. and JenkinsR. B., Improvement of Parkinsonism in Depressed Patients Treated with ECT, American Journal of Psychiatry, 132, pp. 283–285, 1975.
52.
YudofskyS. C., Parkinson's Disease, Depression and Electroconvulsive Therapy: A Clinical and Neurobiologic Synthesis, Comprehensive Psychiatry, 20, pp. 579–581, 1979.
53.
TaylorD. P.RibletL. A.StantonH. C.EisonA. S.EisonM. S., and TempleD. L.Jr., Dopamine and Antianxiety Activity, Pharmacology, Biochemistry and Behavior, 17(suppl 1), pp. 25–35, 1982.
54.
CohnJ. B., Double-blind Comparison of Buspirone and Clorazepate in Anxious Outpatients, American Journal of Medicine, 80: 3B, pp. 10–16, 1986.
55.
BrownR. G.MarsdenC. D.QuinnN., and WykeM. A., Alterations in Cognitive Performance and Affect-arousal State during Fluctuations in Motor Function in Parkinson's Disease, Journal of Neurology and Neurosurgical Psychiatry, 47, pp. 454–465, 1984.
56.
DelisD.DirenfeldL.AlexanderM. P., and KaplanE., Cognitive Fluctuations Associated with On-Off Phenomena in Parkinson's Disease, Neurology, 32, pp. 1049–1052, 1982.
57.
RogersD., Bradyphrenia in Parkinsonism: A Historical Review, Psychological Medicine, 16, pp. 257–265, 1986.
58.
Javoy-AgidF., and AgidY., Is the Mesocortical Dopaminergic System Involved in Parkinson's Disease?Neurology, 30, pp. 1326–1330, 1980.
59.
BrownG. L. and WilsonW. P., Parkinsonism and Depression, Southern Medical Journal, 65, pp. 540–545, 1972.
60.
MayeuxR.SternY.RosenJ., and LevanthalJ., Depression, Intellectual Impairment and Parkinson's Disease, Neurology, 31, pp. 645–650, 1981.
61.
PassafiumeD. and KeefeBollert N., Neuropsychologic Impairments in Patients with Parkinson's Disease, in Neuropsychological Assessment of Neuropsychiatric Disorder, GrantI. and AdamsK. (eds.), Oxford, New York, pp. 374–383, 1986.
62.
MortimerJ. A.PirozzoloF. J.HanschE. C., and WebsterD. D., Relationship of Motor Symptoms to Intellectual Deficits in Parkinson Disease, Neurology, 32, pp. 133–137, 1982.
63.
VillarditaC.SmirniP.Le PiraF.ZappalaG., and NicolettiF., Mental Deterioration, Visuoperceptive Disabilities and Constructional Apraxia in Parkinson's Disease, Acta Neurologica Scandinavica, 66, pp. 112–120, 1982.
64.
MesulamM. M., Principles of Behavioral Neurology, F. A. Davis, Philadelphia, 1985.
65.
WalshF. X.ThomasT. J.LanglaisP. J., and BirdE. D., Dopamine and Homovanillic Acid Concentrations in Striatal and Limbic Regions of Human Brain, Annals of Neurology, 12, pp. 52–55, 1982.
66.
HorelJ.Meyer-LohmannJ., and BrooksV., Basal Ganglia Cooling Disables Learned Arm Movements of Monkeys in the Absence of Visual Guidance, Science, 195, pp. 584–586, 1977.
67.
DieckL.GrotzingerB., and KornhuberH., Voluntary Finger Movement in Man, Cerebral Potentials and Theory, Biological Cybernetics, 23, p. 99, 1976.
68.
SchneiderJ. S., Basal Ganglia Role in Behavior: Importance of Sensory Gating and Its Relevance to Psychiatry, Biological Psychiatry, 19–12, pp. 1693–1710, 1984.
69.
MajJ.RogozZ.SkuzaG., and SowinskaH., Repeated Treatment with Antidepressant Drugs Increases the Behavioural Response to Apomorphine, Journal of Neural Transmission, 60, pp. 273–282, 1984.
70.
PoulosC. X. and HinsonR., Pavlovian Conditional Tolerance to Haloperidol Catalepsy: Evidence of Dynamic Adaptation in the Dopaminergic System, Science, 218, pp. 491–492, 1982.
71.
SchecterM. D., Haloperidol-induced Supersensitivity to the Discrimination of Apomorphine, European Journal of Pharmacology, 74, pp. 343–346, 1981.
72.
SchlemmerR. F.Jr.NarasimhachariN., and DavisJ. M., Dose-dependent Behavioral Changes Induced by Apomorphine in Selected Members of a Primate Social Colony, Journal of Pharmacy and Pharmacology, 32, pp. 285–289, 1980.
73.
SilvaC. C.CamposF., and CarliniE. A., Aggressive Behavior Induced by Apomorphine in Rats Submitted to Four Stressful Situations, Research in Community Psychology and Psychiatric Behavior, 5: 4, pp. 353–367, 1980.
74.
WiseR. A., Neuroleptics and Operant Behavior: The Anhedonia Hypothesis, Behavioral and Brain Sciences, 5, pp. 39–87, 1982.
75.
ZeigerK. D. and CarliniE. A., The Persistence of Hyperresponsiveness to Apomorphine in Rats Following REM Sleep Deprivation and the Influence of Housing Conditions, European Journal of Pharmacology, 80, pp. 99–104, 1982.
76.
BrownP.CleghornJ. M.BrownG. M., and BlackallM. H., The Neuroendocrinology of Schizophrenia, International Journal of Mental Health, 9, pp. 108–139, 1981.
77.
SeemanP., Brain Dopamine Receptors, Pharmacology Review, 32, pp. 230–313, 1981.
78.
LackovicZ. and ReljaM., Evidence for a Widely Distributed Peripheral Dopaminergic System, Federation Proceedings, 42, pp. 3000–3004, 1983.
79.
McClellandD. C.PatelV.StierD., and BrownD., The Relationship of Affiliative Arousal to Dopamine Release, Motivation and Emotion, 11: 1, pp. 51–66, 1987.
80.
JennerodM., The Brain Machine, Harvard, Cambridge, MA, 1985.
81.
RogersD., The Motor Disorders of Severe Psychiatric Illness: A Conflict of Paradigms, British Journal of Psychiatry, 147, pp. 221–232, 1985.
82.
ZanoneP. and HauertC., For a Cognitive Conception of Motor Processes, European Bulletin of Cognitive Psychology, 7: 2, pp. 109–129, 1987.
83.
MacKeyM. and GlassL., Oscillation and Chaos in Physiological Control Systems, Science, 197, pp. 287–289, 1977.
84.
RappP., Oscillations and Chaos in Cellular Metabolism and Physiological Systems, in Chaos, HoldenA. V. (ed.), Princeton University Press, city? pp. 179–210, 1987.
85.
KingR.BarchasJ., and HubermanB., Chaotic Behaviour in Dopamine Neurodynamics, Proceedings of the National Academy of Science, 81, pp. 1244–1247, 1984.
86.
DeLongM., Possible Involvement of Central Pacemakers in Clinical Disorders of Movement, Federation Proceedings, 37, pp. 2171–2175, 1978.
87.
StilesR. and PozosR., A Mechanical-reflex Oscillator Hypothesis for Parkinsonian Hand Tremor, Journal of Applied Physiology, 40, pp. 990–998, 1976.
